EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Recombinant derivatives of the major birch pollen allergen Bet v 1, which induce fewer symptoms and lower mediator release and eosinophil activation than rBet v 1 wild-type in nasal challenges in birch pollen allergic patients






Allergy (Copenhagen) 56(Supplement 68): 94

Recombinant derivatives of the major birch pollen allergen Bet v 1, which induce fewer symptoms and lower mediator release and eosinophil activation than rBet v 1 wild-type in nasal challenges in birch pollen allergic patients



Accession: 035619164



Related references

van Hage-Hamsten, M.; Johansson, E.; Roquet, A.; Peterson, C.; Andersson, M.; Greiff, L.; Vrtala, S.; Valenta, R.; Grönneberg, R., 2002: Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Genetic engineering of the major birch pollen allergen (Bet v 1) has led to the generation of recombinant Bet v 1 derivatives with markedly reduced IgE-binding capacity, but with retained T cell activating ability. To compare the mucosal reactivit...

Van Hage Hamsten, M.; Johansson, E.; Roquet, A.; Peterson, C.; Andersson, M.; Greiff, L.; Vrtala, S.; Valenta, R.; Gronneberg, R., 2002: Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Background: Genetic engineering of the major birch pollen allergen (Bet v 1) has led to the generation of recombinant Bet v 1 derivatives with markedly reduced IgE-binding capacity, but with retained T cell activating ability. Objective: To compar...

Nopp, A.; Halldén, G.; Lundahl, J.; Johansson, E.; Vrtala, S.; Valenta, R.; Grönneberg, R.; Van Hage-Hamsten, M., 2000: Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. Background: Nearly 60% of birch pollen-allergic patients react exclusively to Bet v 1. With use of the skin blister model, previously only established for installation of crude allergens, we have for the first time characterized the inflammatory r...

Larenas-Linnemann, Désirée., 2010: Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Oralair Birch is a dissolving tablet being developed for sublingual immunotherapy (SLIT) of allergic rhinitis caused by birch pollen allergy. Oralair Birch is being developed by Stallergenes SA and Canadian licensee Paladin Labs Inc. Oralair Birch...

Gafvelin, G.; Thunberg, S.; Kronqvist, M.; Grönlund, H.; Grönneberg, R.; Troye-Blomberg, M.; Akdis, Mübeccel.; Fiebig, H.; Purohit, A.; Horak, F.; Reisinger, Jürgen.; Niederberger, V.; Akdis, C.A.; Cromwell, O.; Pauli, G.; Valenta, R.; van Hage, M., 2005: Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Background: Recently, recombinant hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, were used to treat birch-pollen-allergic patients in a double-blind, placebo-controlled, multi-centre immunotherapy study. The aim of this st...

Niederberger, V.; Pauli, G.; Grönlund, H.; Fröschl, R.; Rumpold, H.; Kraft, D.; Valenta, R.; Spitzauer, S., 1998: Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. Pollen from trees of the order Fagales are important allergen sources in most parts of the world. Clinical, immunochemical, and molecular biology studies indicate that they contain cross-reactive allergens. The major birch pollen allergen, Bet v 1...

Mari, A.; Wallner, M.; Ferreira, F., 2003: Fagales pollen sensitization in a birch-free area: a respiratory cohort survey using Fagales pollen extracts and birch recombinant allergens (rBet v 1, rBet v 2, rBet v 4). Birch allergy is one of the most common pollinosis in areas where exposure to high levels of birch pollen is common. Little is known about birch sensitivity in areas without birch pollen exposure and reactivity to birch-related species within the...

Mari, A.; Wallner, M.; Ferreira, F., 2003: Fagales pollen sensitization in a birch-free area: a respiratory cohort survey using Fagales pollen extracts and birch recombinant allergens (rBet v 1, rBet v 2, rBet v 4). Birch allergy is one of the most common pollinosis in areas where exposure to high levels of birch pollen is common. Little is known about birch sensitivity in areas without birch pollen exposure and reactivity to birch-related species within the...

van Hage-Hamsten, M.; Kronqvist, M.; Zetterström, O.; Johansson, E.; Niederberger, V.; Vrtala, S.; Grönlund, H.; Grönneberg, R.; Valenta, R., 1999: Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. Background: More than 95% of birch pollen-allergic subjects react with the major birch pollen allergen, Bet v 1, and almost 60% of them are sensitized exclusively to this allergen. Objective: The aim of this study was to compare the in vivo biolog...

Godnic-Cvar, J.; Susani, M.; Breiteneder, H.; Berger, A.; Havelec, L.; Waldhör, T.; Hirschwehr, R.; Valenta, R.; Scheiner, O.; Rüdiger, H.; Kraft, D.; Ebner, C., 1997: Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen. Atopic allergens produced by recombinant DNA methods are promising tools for diagnosis and therapy of Type I allergy. To evaluate the immunologic properties of these molecules, it is necessary to compare them with natural allergens in vitro and in...